27 completed, 20 recruiting, 13 active not recruiting, 11 terminated. 45 Phase 1, 38 Phase 2, 4 Early Phase 1, 1 Phase 3.
Follow Recurrent Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Recurrent Diffuse Large B-Cell Lymphoma trials Research Report on Recurrent Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-10-07 | 2026-10-21 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | University of California, Davis | 34 | 2025-08-07 | 2026-07-08 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2025-10-20 |
| Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma RC19D2 cell injection - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Recruiting | Beijing Yongtai Ruike Biotechnology Company Ltd | 25 | 2023-09-05 | 2024-08-27 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-08-01 | 2026-02-23 |
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Recruiting | City of Hope Medical Center | 9 | 2023-07-20 | 2026-02-04 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
Showing 20 of 79. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (79) · Lymphoma, Mantle-Cell (28) · Lymphoma, Follicular (26) · Lymphoma, B-Cell (17) · Lymphoma, B-Cell, Marginal Zone (17) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, Non-Hodgkin (16) · Burkitt Lymphoma (10) · Lymphoma, T-Cell (7) · Hodgkin Disease (6) · Multiple Myeloma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Waldenstrom Macroglobulinemia (4) · Hematologic Neoplasms (3) · Chromosome 17 deletion (2)
Hemic and Lymphatic Diseases (79) · Immune System Diseases (78) · Immunoproliferative Disorders (78) · Lymphatic Diseases (78) · Lymphoproliferative Disorders (78) · Neoplasms by Histologic Type (78) · Lymphoma (77) · Neoplasms (77) · Lymphoma, Non-Hodgkin (63) · Lymphoma, B-Cell (62) · Hematologic Diseases (23) · Pathologic Processes (21) · Pathological Conditions, Signs and Symptoms (21) · Disease Attributes (20) · Leukemia (19)
Rituximab (21) · CT-P10 (19) · Magnetic Resonance Spectroscopy (19) · Cyclophosphamide (17) · Specimen Handling (16) · Biopsy (12) · Etoposide (12) · Lenalidomide (10) · fludarabine (10) · Leukapheresis (9) · fludarabine phosphate (9) · Carboplatin (8) · Cytarabine (8) · ibrutinib (8) · Ifosfamide (7)
City of Hope Medical Center (13) · National Cancer Institute (NCI) (12) · Fred Hutchinson Cancer Center (9) · M.D. Anderson Cancer Center (9) · University of Washington (5) · Mayo Clinic (3) · University of California, Davis (3) · David Bond, MD (2) · Jonsson Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · Rutgers, The State University of New Jersey (2) · SWOG Cancer Research Network (2) · University of Nebraska (2) · Vanderbilt-Ingram Cancer Center (2) · AIDS Malignancy Consortium (1)
United States (76) · Canada (1) · China (1) · Denmark (1)
Alex F Herrera (3) · Jordan Gauthier (3) · Yago L Nieto (3) · David Bond, MD (2) · Joseph M Tuscano (2) · Kami Maddocks, MD (2) · Stephen D. Smith (2) · Alex Herrera (1) · Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Alexey Danilov (1) · Amrita Y. Krishnan MD, MD (1) · Ariela Noy (1) · Beth A Christian (1) · Beth Christian, MD (1)
PMID 34515338, PMID 25145344, PMID 27111235, PMID 29038338, PMID 29386196, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31648294, PMID 32430507, PMID 32499241, PMID 32603426, PMID 32967009, PMID 33786583, PMID 33942298, PMID 34435552, PMID 34492703, PMID 34666344, PMID 35015819, PMID 36631449, PMID 37300573, PMID 37339586, PMID 37470137, PMID 37632592, PMID 37774014, PMID 37903325, PMID 39333103, PMID 39352751, PMID 39820359, PMID 41595202, PMID 41845899, PMID 42389828
P30CA033572 (8), P50CA107399 (4), P30CA015704 (3), P30CA016672 (3), P30CA093373 (3), UM1CA186709 (3), P01CA018029 (2), P30CA016058 (2), P30CA036727 (2), P30CA072720 (2), P50CA097274 (2), R01CA136551 (2), U10CA180888 (2), UM1CA121947 (2), UM1CA186644 (2)